Our Phase 3 International Linked Clinical Trials
Exenatide (also known as Bydureon) is a clinically available and widely used drug for the treatment of type 2 diabetes. Cure Parkinson’s is investigating the repurposing of exenatide to treat the progression of Parkinson’s.
Exenatide and Parkinson’s
Ambroxol is already being used to treat respiratory conditions. Cure Parkinson’s has supported a phase 2 clinical trial to test efficacy in treating Parkinson’s, and is supporting a further phase 3 clinical trial, designed to test the long-term efficacy of ambroxol in slowing the progression of Parkinson’s.
Ambroxol and Parkinson’s
The Phase 2 International Linked Clinical Trials
This medication is already in use as a treatment for inflammation and the AZA-PD Study is looking at dampening down the immune response as a way of slowing the progression of Parkinson’s. The trial is being conducted in Cambridge (UK) and is supported by Cure Parkinson’s.
Read more about Azathioprine and Parkinson’s
Anle138b is a promising drug that targets the toxic accumulation of alpha-synuclein with the aim of alleviating neurodegenerative symptoms. This study is now recruiting people with Parkinson’s to participate.
The Anle138b Trial – find out more.
UDCA is used in the treatment of gallstones and has been determined to have beneficial effects on mitochondrial function in models of Parkinson’s. The UP study – UDCA in Parkinson’s, supported by Cure Parkinson’s, has now completed and we are awaiting results.
Read more about UDCA and Parkinson’s
Deferiprone is an iron chelator – a class of medication used to reduce iron levels in the body. There is evidence that reducing iron in the brain can be beneficial for Parkinson’s.
Read more about Deferiprone and Parkinson’s
A similar drug to exenatide, this drug is designed to better access the brain. NLY-01 was highly prioritised by the International Linked Clinical Trials (iLCT) committee in 2017. Similar drugs to NLY-01 already approved for the treatment of type 2 diabetes include exenatide, lixisenatide, and liraglutide – all three of these drugs have been or are being trialled in Parkinson’s through the Cure Parkinson’s iLCT programme. We are delighted to see Neuraly move this drug into a phase 2 clinical trial in the U.S.
Find out more about NLY-01 here.
The Australian Parkinson’s Mission (APM) is a 5-year clinical trial project funded by the Australian Federal Government. The first trial is testing three drugs that have been prioritised by the International Linked Clinical Trials initiative, comparing them with a single placebo. Further APM trials are being set up.
Read more about the APM